My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

53.99 +2.03 (+3.92%)

Streaming Delayed Price Updated: 3:53 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗

February 24, 2026

Via Chartmill

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.

Via The Motley Fool

Topics Regulatory Compliance

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Via The Motley Fool

The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026

March 09, 2026

As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Vaxcyte's Chief Technical Ops Officer Sells Shares ↗

January 03, 2026

Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.

Via The Motley Fool

Topics Regulatory Compliance

These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗

November 18, 2025

Via MarketBeat

Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗

September 30, 2025

Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with yields near historic lows and spreads tight.

Via Benzinga

Topics Bonds

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗

September 11, 2025

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.

Via Benzinga

Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

August 07, 2025

Via Benzinga

Vaxcyte (PCVX) Q2 Loss Widens 11% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 01, 2025

Via Benzinga

Top stock movements in today's session. ↗

March 31, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Monday's session: top gainers and losers ↗

March 31, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 31, 2025

Via Benzinga

These stocks are gapping in today's session ↗

March 31, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗

March 31, 2025

Via Benzinga

Topics Stocks

Monday's pre-market session: top gainers and losers ↗

March 31, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March ↗

March 31, 2025

Via Benzinga

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine ↗

March 31, 2025

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 31, 2025

Via Benzinga

One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗

March 15, 2025

Via The Motley Fool

Topics Stocks

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.